This is also highlighted by the enhanced incidence of TB reactivation during treatment with biologicals targeting TNF, which are used in treating inflammatory disorders such as rheumatoid arthritis, Crohn's disease, and psoriasis [21]. Here, TNF is linked to tuberculosis.